[Effect of Pharmachim's cimetidine preparation in 200- and 1000-mg ampules on the gastric secretion of duodenal ulcer patients].
Gastric secretion was studied in 30 patients with duodenal ulcer. The trial was carried out in the following way: the patients were divided into two groups of 10 patients each. To the first group of 10 patients on the first day of the examination pentagastrin test was performed by subcutaneous application of Acignost (GDR) in a dose of 6 micrograms/kg body mass; on the second day the same dose of Acignost was injected with simultaneous i. v. application of 200 mg of Cimetidin-Pharmachim. To the second group of 10 patients on the first day pentagastrin test was also performed but on the second day the same dose of Acignost was injected together with 1000 mg of Cimetidin. The i. v. application of 200 mg and 1000 mg of Cimetidin-Pharmachim inhibits significantly the gastric secretion and acid production in patients with duodenal ulcer stimulated by Acignost. The inhibiting action of Cimetidin begins 30 minutes after its application and lasts more than an hour and is better expressed by injecting of 1,000 mg than of 200 mg Cimetidin-Pharmachim. Cimetidin-Pharmachim for parenteral application exerts a strong inhibiting action on gastric secretion and acid production. Its use is recommended for everyday practice since its efficacy equals that of the English drug Tagamet (Smith Kline) for parenteral application.